RESEARCH ARTICLE

Open Access

Limited effect of anti-rheumatic treatment on 15-prostaglandin dehydrogenase in rheumatoid arthritis synovial tissue

Karina Roxana Gheorghe¹, Syed Sadique¹, Patrick Leclerc¹, Helena Idborg¹, Ivonne Wobst², Anca Irinel Catrina¹, Per-Johan Jakobsson¹ and Marina Korotkova^{1,3*}

Abstract

Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disease in which prostaglandin E₂ (PGE₂) displays an important pathogenic role. The enzymes involved in its synthesis are highly expressed in the inflamed synovium, while little is known about 15-prostaglandin dehydrogenase (15-PGDH) that metabolizes PGE₂. Here we aimed to evaluate the localization of 15-PGDH in the synovial tissue of healthy individuals or patients with inflammatory arthritis and determine the influence of common RA therapy on its expression.

Methods: Synovial tissue specimens from healthy individuals, psoriatic arthritis, osteoarthritis and RA patients were immunohistochemically stained to describe the expression pattern of 15-PGDH. In addition, the degree of enzyme staining was evaluated by computer analysis on stained synovial biopsies from two groups of RA patients, before and after RA specific treatment with either intra-articular glucocorticoids or oral methotrexate therapy. Prostaglandins derived from the cyclooxygenase (COX) pathway were determined by liquid-chromatography mass spectrometry in supernatants from interleukin (IL) 1 β -activated fibroblast-like synoviocytes (FLS) treated with methotrexate.

Results: 15-PGDH was present in healthy and inflamed synovial tissue, mainly in lining macrophages, fibroblasts and vessels. Intra-articular glucocorticoids showed a trend towards reduced 15-PGDH expression in RA synovium ($p = 0.08$) while methotrexate treatment left the PGE₂ pathway unaltered both in biopsies *ex vivo* and in cultured FLS.

Conclusions: Early methotrexate therapy has little influence on the expression of 15-PGDH and on any of the PGE₂ synthesizing enzymes or COX-derived metabolites. Thus therapeutic strategies involving blocking induced PGE₂ synthesis may find a rationale in additionally reducing local inflammatory mediators.

Introduction

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and extensive proliferation within the joint synovial tissue and by recruitment and activation of immune cells and subsequent cartilage and bone destruction. Rheumatoid joint displays an activated prostaglandin E₂ (PGE₂) pathway, and there are high levels of this mediator in the synovial fluid and strong expression in the synovium of its synthesizing

enzymes, microsomal prostaglandin E₂ synthase 1 (mPGES-1) as well as cyclooxygenase (COX) 1 and 2 [1]. Whereas COX-1 is considered a constitutive enzyme present under basal conditions, COX-2 is inflammation-induced [2] and co-localizes with mPGES-1 in the synovial tissue [3]. The deleterious role of PGE₂ in the pathogenesis of RA has already been established and occurs through multiple mechanisms. PGE₂ sustains inflammatory pathways by promoting expansion of auto-aggressive T helper 17 (Th17) cells [4], increases angiogenesis within the proliferating synovium, and regulates cartilage and bone metabolism by stimulation of osteoclast and matrix metalloproteinase activity. Pro-inflammatory cytokines, such as

* Correspondence: marina.korotkova@ki.se

¹Department of Medicine, Rheumatology Unit, Karolinska Institute/Karolinska University Hospital Solna, Stockholm, 171 76 Sweden

Full list of author information is available at the end of the article

tumor necrosis factor (TNF) and interleukin-1-beta (IL-1 β), that orchestrate the pathological events in this disease are known inducers of mPGES-1 and COX-2 expression [5].

The levels of PGE₂ are determined not only by its synthesis but also by the rate of degradation. Most of the prostaglandin inactivation occurs through the action of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), which converts PGE₂ to a metabolite with greatly reduced biological activity [6] and is thus the main mechanism for PGE₂ clearance. 15-PGDH is ubiquitously expressed in most mammalian tissues [6]. In humans, IL-6 [7] and transforming growth factor-beta (TGF β) regulate its expression in prostate and colon cancer, respectively, whereas TNF downmodulates it in colonocytes [8]. In addition, mediators controlling PGE₂ formation reciprocally stimulate COX-2 while reducing 15-PGDH expression [9]. 15-PGDH decrease or loss was demonstrated in gastric [10], lung [11], and thyroid [12] tumors and results in increased malignant cell proliferation and cancer progression. In addition, reduced expression of 15-PGDH contributes to the elevated PGE₂ levels observed in the systemic inflammatory response [13] or in the inflamed mucosa of patients with inflammatory bowel disease [8].

Recent reports demonstrated 15-PGDH synthesis in mouse articular chondrocytes and an inverse regulation of mPGES-1 and 15-PGDH by adipocyte-derived factors in these cells, resulting in boosted PGE₂ levels [14]. Also, mechanical stress increases 15-PGDH mRNA expression in this system [15]. However, the presence and localization of this enzyme in human synovial tissue remain largely unknown.

Intra-articular glucocorticoids (GCs) are often used as efficient adjuvant therapy in RA to control for local inflammation. One of the mechanisms by which they achieve their anti-inflammatory effect relies also on inhibition of synovial mPGES-1 and COX-2 expression and formation of PGE₂ [3]. Earlier reports evaluating the influence of dexamethasone on 15-PGDH demonstrated either induced expression in A549 cells [16] or inhibition of *in vitro* stimulated enzyme expression in a monocyte cell line [17].

In patients with RA, one of the most efficient drugs used in most cases as first-line therapy is methotrexate [18]. Its interference with the cellular folate metabolism results in immunosuppressive effects by inhibition of synovial inflammatory cell proliferation and enhancement of adenosine release. The influence of methotrexate on PGE₂ production appears controversial; reports demonstrate inhibitory action in whole blood of patients with RA [19] and in fibroblast-like synoviocytes (FLSs) [20], but studies also point to no effect on PGE₂ release by FLSs [21,22].

We undertook this study to investigate the distribution of 15-PGDH in synovial tissue and the effects of methotrexate therapy on the synovial expression of the PGE₂ pathway enzymes in patients with newly diagnosed RA and *in vitro* in cultured FLSs. Moreover, we analyzed the change in expression pattern for 15-PGDH induced by local administration of GCs known to have potent anti-inflammatory properties.

Materials and methods

Patients and clinical data

Synovial biopsies were collected at the time of surgical joint replacement from eight patients with RA and five with osteoarthritis (OA). In addition, synovial samples from three healthy individuals and three patients with psoriatic arthritis (PsA) were obtained by arthroscopy. The biopsies were used for detection and cellular localization of synovial 15-PGDH.

To investigate the effects of anti-rheumatic treatment on the enzymes of the PGE₂ cascade, synovial biopsies were collected from two cohorts of patients. In the first group, 13 patients with newly diagnosed RA were enrolled; the median time period since diagnosis was 7 days, and the median time since the beginning of symptoms was 6.5 months. Table 1 illustrates the clinical and laboratory data of the patient cohort. These patients had active disease with a Disease Activity Score in 28 joints (DAS28) of greater than 3.2 (mean of 5.7). All patients fulfilled the American College of Rheumatology criteria for RA [23]. At baseline and 1 year after inclusion in the

Table 1 Demographic, clinical, and laboratory data of the methotrexate study cohort

Characteristics of cohort	Value
Number of patients	13
Median age (range), years	56 (32-78)
Number of males/females	4/9
Median interval from diagnosis (range), days	7 (1-25)
Median duration of symptoms (range), months	6.5 (2-12)
ACPA-positive patients, number (percentage)	6 (46)
Rheumatoid factor-positive patients, number (percentage)	9 (69)
Number of patients taking oral corticosteroids	2
Number of patients taking NSAIDs	10
Median duration between biopsies (range), days	58 (45-70)
Number of patients presenting erosions (percentage)	
At baseline	2 (15)
After 1 year	7 (53)
Mean DAS28 (minimum, maximum)	
At baseline	5.7 (3.9, 6.7)
After 3 months	3.8 (1.8, 5.8)

ACPA, anti-cyclic citrullinated peptide antibody; DAS28, Disease Activity Score in 28 joints; NSAID, non-steroidal anti-inflammatory drug.

study, plane radiographs of the affected joint were evaluated for the presence of erosions. DAS28 was assessed at baseline and at a median of 3 months after treatment initiation. Patients were assigned to start methotrexate therapy with an initial dosage of 10 mg/week, which was increased in a stepwise manner to achieve the final dosage of 20 mg/week after 3 weeks. Synovial biopsies were obtained by arthroscopy from the same inflamed joint before methotrexate initiation and after a median of 8 weeks. Oral non-steroidal anti-inflammatory drugs (NSAIDs) and GCs in doses of up to 10 mg daily were allowed, as was a maximum of three intra-articular GC injections in joints other than the one biopsied.

In the second group, 10 patients who had RA and active knee arthritis were recruited to the study. The clinical features of this patient group were published previously [24]. All patients in the second group received an intra-articular injection of 40 mg of triamcinolone hexacetonide. Synovial biopsies were obtained prior to and a median of 10 days after treatment. All other anti-rheumatic medication was kept unchanged 2 weeks before the first arthroscopy and for the rest of the study period. All investigations were approved by the ethics committee of the Karolinska University Hospital, and participants gave written informed consent to participate in the study.

Immunohistochemical evaluation

Frozen serial biopsy sections were fixed in 2% formaldehyde, and immunohistochemical staining was performed by using rabbit polyclonal anti-serum raised toward mPGES-1 [1], rabbit polyclonal anti-15-PGDH (Novus Biologicals, Littleton, CO, USA) and anti-COX-1 (Cayman Chemical Company, Ann Harbor, MI, USA), and mouse monoclonal anti-COX-2 (CX229; Cayman Chemical Company) antibodies in accordance with a published protocol [25]. Stained sections were quantitatively evaluated by computer-based image analysis, and results were expressed as the percentage of positive stained area versus total tissue staining. For immunofluorescence experiments, sections were incubated with a mixture of primary antibodies against 15-PGDH and cell markers for macrophages (CD163, clone Ber-MAC3), fibroblasts (prolyl-4-hydroxylase, clone 5B5), B cells (CD20, clone L26) (all from Dako-Cytomation, Glostrup, Denmark), T cells (CD3, SK7; BD Biosciences, San Jose, CA, USA), and endothelial cells (CD31, clone EN4; Novakemi, Handen, Sweden) followed by the addition of secondary antibodies conjugated to Alexa 546 or Alexa 488 (Invitrogen Corporation, Carlsbad, CA, USA).

In vitro culture of fibroblast-like synoviocytes and measurement of prostaglandins

Commercially available FLSs (Dominion Pharmakine, S.L., Bizkaia, Spain) from patients with RA were grown

in Dulbecco's modified Eagle's medium supplemented with 10% human serum and penicillin streptomycin (100 units/mL) in a humidified atmosphere containing 5% CO₂ at 37°C. When reaching confluence, cells were passaged by gentle trypsinization and used between passages 4 and 6. The cells were incubated for 48 hours with 10 ng/mL IL-1 β (R&D Systems, Abingdon, UK) in the presence or absence of 10 or 250 μ M methotrexate. Unstimulated cells were used as controls. After treatment, supernatants were collected and frozen at -20°C until analyzed. Cells were trypsinised, washed twice in phosphate-buffered saline (PBS), and harvested for subsequent Western blot analysis.

Prostaglandin profiling of the primary prostaglandins (PGE₂, PGD₂, and PGF_{2 α}) and of the metabolites of PGI₂ and thromboxane A₂ (TxA₂) - 6-keto PGF_{1 α} and TxB₂, respectively - was accomplished by using liquid chromatography tandem mass spectrometry (LC-MS-MS). Cell culture supernatants were extracted with an Oasis HLB Extraction Plate (Waters Corporation, Milford, MA, USA) and analyzed by high-performance liquid chromatography by using Waters 2795 HPLC (Waters Corporation) coupled to a triple quadrupole mass spectrometer (Acquity TQ Detector; Waters Corporation). PGE₂, PGD₂, PGF_{2 α} , TxB₂, 6-keto-PGF_{1 α} , and their corresponding deuterated standards were detected by using multiple reaction monitoring and quantified by using internal standard methodology and QuanLynx software (Waters Corporation).

Western blot analysis of enzymes

Cells were harvested after the different treatments and protein was extracted by using cell lysis buffer (Pierce, Rockford, IL, USA) in accordance with the instructions of the manufacturer. Total protein concentration was determined by using the NanoDrop technique, and equal amounts of protein were separated on 4% to 12% NuPage polyacrylamide gels (Invitrogen Ltd., Paisley, UK). The resolved proteins were blotted onto polyvinylidene fluoride membranes (Pall Life Sciences, Pensacola, FL, USA), which were further blocked in PBS-Tween-20 buffer containing 5% (wt/vol) non-fat dry milk for 1 hour at room temperature. Incubation with primary antibodies rabbit polyclonal anti-serum against mPGES-1, rabbit polyclonal anti-COX-2 (Cayman Chemical Company), rabbit polyclonal anti-15-PGDH (Cayman Chemical Company), or mouse monoclonal anti- β -actin (NeoMarkers, Fremont, CA, USA) was performed overnight at 4°C. After washing in 0.05% TTBS (Tris-Tween-buffered saline), the membranes were incubated with horseradish peroxidase-linked anti-rabbit IgG from donkey (GE Healthcare, Stockholm, Sweden), washed extensively in 0.1% TTBS, and finally visualized by a chemiluminescence detection kit (Thermo Scientific, Rockford, IL, USA) on film

(Amersham Hybond; GE Healthcare, Buckinghamshire, UK).

Statistical analysis

For statistical analysis of the methotrexate and GC cohorts, we used the Wilcoxon test for paired samples, followed by Bonferroni corrections for multiple comparisons, whereas *in vitro* data were analyzed by the Mann-Whitney test for unpaired samples. *P* values of less than 0.05 were considered significant.

Results

Distribution of 15-PGDH in rheumatoid arthritis synovial tissue

All RA biopsy samples analyzed displayed 15-PGDH expression (Figure 1a). Its presence in RA synovial tissue was prominent in the synovial lining but also in scattered sublining macrophages and inflammatory infiltrates as well as vessels. Expression of 15-PGDH among patients was, nonetheless, variable; staining was strong and extensive in some patients and weak and confined mostly to the synovial membrane in others. In addition, the enzyme was present, albeit to a lesser extent, in healthy synovial tissue and in synovium from patients with OA and those with PsA (Figure 1b-d). Similarly to

RA, the enzyme was found mainly in the lining layer in healthy tissue, PsA, and OA, although the expression was somewhat weaker in the lining synovial cells of healthy individuals compared with RA.

Most 15-PGDH-expressing cells were identified by double-immunofluorescence as CD163-positive synovial macrophages and fibroblasts in RA synovium (Figure 2a left and middle panels). In addition, most sublining vessels stained positively for 15-PGDH in endothelial cells (Figure 2 right panel) whereas CD20-positive B cells and CD3-positive T cells essentially lacked 15-PGDH enzyme (data not shown).

Clinical evaluation and response to treatment

Out of the 13 patients included in the methotrexate study cohort, seven were responders, defined as those who had good or moderate response to treatment according to the European League Against Rheumatism (EULAR) criteria, and six were non-responders. The overall mean DAS28 decreased significantly to 3.8 after 3 months of treatment. All patients receiving intra-articular GCs were clinical responders as assessed by the local clinical examination of the joint and macroscopic evaluation of the local inflammation during the second arthroscopy.

Figure 1 Expression of 15-prostaglandin dehydrogenase (15-PGDH) in healthy and inflamed synovial tissue. Immunohistochemical staining reveals positive (brown) staining for 15-PGDH (hematoxylin counterstained) in synovial tissue from healthy individuals (a) and patients with rheumatoid arthritis (b), osteoarthritis (c), or psoriatic arthritis (d). Original magnifications: $\times 250$ (a, b), $\times 100$ (c, d).

Figure 2 Cellular localization of 15-prostaglandin dehydrogenase (15-PGDH) in rheumatoid arthritis synovial tissue and the effects of anti-rheumatic treatment on its expression. (a) Double-immunofluorescence images show staining for 15-PGDH-positive (red) cells and cell marker staining (green) for macrophage CD163, fibroblast prolyl-4-hydroxylase, and endothelial cell CD31. Merged images display double-stained cells in yellow. Original magnification: $\times 400$. Light microscopy pictures of representative synovial biopsy sections show immunohistochemical positive (brown) staining for 15-PGDH before and after intra-articular treatment with glucocorticoids **(b)** and before and 8 weeks after initiation of methotrexate therapy **(c)** (hematoxylin counterstained). Graphs display the comparative 15-PGDH expression in rheumatoid arthritis synovial tissue before and after treatment with glucocorticoids or methotrexate as a percentage of the positive stained area versus the total tissue area. GC, glucocorticoids; Mtx, methotrexate.

Effects of intra-articular steroid therapy on the expression of 15-PGDH in rheumatoid arthritis synovial tissue

We have earlier reported that intra-articular GC treatment downregulated the expression of PGE₂-synthesizing enzymes in the rheumatoid synovium. Here, our results demonstrated that local GC therapy resulted in reduced expression of 15-PGDH in nine patients but that two patients showed increased values after therapy (Figure 2b). Overall, although no statistical difference ($P = 0.08$) was detected before or after local GC injection, there was a clear trend toward diminished enzyme expression following therapy.

Effects of methotrexate therapy on the expression of 15-PGDH and related enzymes in rheumatoid arthritis joint

We then studied the effect of oral methotrexate therapy on 15-PGDH and found that 8 weeks of oral methotrexate

treatment did not significantly change the synovial expression level of 15-PGDH (Figure 2c). As the local PGE₂ production is determined by its biosynthesis and degradation, we also examined whether methotrexate affects the biosynthetic enzymes. No effects of methotrexate on synovial expression of mPGES-1, COX-1, and COX-2 were detected (Figure 3). Stratifying patients according to response to treatment, presence of anti-cyclic citrullinated peptide antibodies, or erosion progression did not show any significant difference in enzyme expression between or within the groups (data not shown). We also found a similar overall staining pattern for PGE₂-related enzymes irrespectively of NSAID treatment (data not shown).

In unstimulated *in vitro* cultured FLSs, low levels of PGE₂ formation were mirrored by undetectable expression of COX-2 and mPGES-1 (Figure 4a, b). Still, FLSs displayed low 15-PGDH amounts even in basal conditions,

Figure 3 Effects of methotrexate on the expression of prostaglandin E_2 biosynthetic enzymes in rheumatoid synovium.

Immunohistochemical evaluation of positive staining for microsomal prostaglandin E_2 synthase 1 (mPGES-1), cyclooxygenase 1 (COX-1), and COX-2 in synovial tissue biopsies before and 8 weeks after initiation of methotrexate treatment. Results are expressed as a percentage of the positive stained area versus the total tissue area.

and this is in line with the presence of this enzyme in most tissues. As expected, IL-1 β determined a strong increase in PGE $_2$ production along with upregulation of enzyme expression. The increase in 15-PGDH expression following IL-1 β stimulation was, however, modest in comparison with the dominant upregulation of the synthesizing

enzymes mPGES-1 and COX-2, explaining the net effect of increased PGE $_2$ synthesis. However, the addition of methotrexate in either low or high concentration did not abrogate the IL-1 β -induced effects on any studied enzyme expression or the PGE $_2$ formation. Furthermore, analysis of the prostanoid profile by LC-MS-MS in supernatants

Figure 4 Effects of methotrexate on the prostaglandin production by rheumatoid arthritis fibroblast-like synoviocytes (FLSs).

Synovial fibroblasts were left untreated or activated with 10 ng/mL interleukin-1-beta (IL-1 β) in the absence or presence of 10 or 250 μ M methotrexate for 48 hours. After treatment, total protein was isolated and assayed for enzyme expression, while β -actin was used as loading control. Supernatants were analyzed for prostanoid content by using liquid chromatography tandem mass spectrometry. **(a)** Analysis of prostaglandin E_2 (PGE $_2$) formation in control and IL-1 β -stimulated FLSs with or without methotrexate. **(b)** Representative Western blot results show expression of microsomal prostaglandin E_2 synthase 1 (mPGES-1), cyclooxygenase 2 (COX-2), and 15-prostaglandin dehydrogenase (15-PGDH) in rheumatoid arthritis FLSs. **(c)** Analysis of PGD $_2$, PGF $_{2\alpha}$, and the metabolites of PGI $_2$ and TxA $_2$ (6-keto PGF $_{1\alpha}$ and TxB $_2$, respectively) in culture supernatants indicates the amount formed after 48 hours of incubation. Horizontal lines indicate median values, and whiskers indicate range values ($n = 4$). Ctrl, control; Mtx, methotrexate; Tx, thromboxane.

from stimulated and unstimulated FLSs showed that methotrexate had no influence on the formation of any of the lipid mediators derived from the COX pathway, as demonstrated by detection of PGE₂, PGD₂, and PGF_{2α} and metabolites of PGI₂ or TxA₂ (Figure 4c).

Discussion

The contribution of the PGE₂ pathway to the RA pathogenic process has been well established, and most studies have focused on PGE₂ and its inflammation-dependent synthesizing enzymes. However, 15-PGDH, the enzyme responsible for the degradation of PGE₂, has received little attention in this context, although its level of expression ultimately determines the availability of PGE₂.

We described here for the first time the distribution pattern of 15-PGDH in synovial tissue in both pathological (inflammatory) and healthy conditions. 15-PGDH was present in patients with RA and was localized mostly in the lining macrophages and sublining fibroblasts and vessels. This finding is in agreement with localization of the mPGES-1 and COX enzymes in RA synovial tissue [1], indicating the possibility for local regulation and balance of formation and removal of PGE₂. An alternative view is that, in an effort to overcome the high prostaglandin burden in RA, 15-PGDH expression increases as a protective mechanism. Furthermore, the enzyme was present in OA and PsA synovium, and this is in line with the association of these conditions with variable degrees of inflammation in synovial tissue. To a lesser extent, we also identified 15-PGDH in the synovial lining of healthy individuals, indicating constitutive formation of PGE₂ in synovial tissue. Expression of PGE₂ pathway enzymes has been reported in non-inflammatory conditions in kidney [26] and muscle [27], suggesting a possible role for basal PGE₂ production in local tissue homeostasis.

Intra-articular GCs relieve local symptoms in the inflamed RA joint and are successfully used as add-on therapy to control for occasional bouts of inflammation. In this study, we demonstrated that GC injections may decrease the expression of 15-PGDH in synovial tissue that in turn, may promote local accumulation of PGE₂. However, previous data from our group showed reduced expression of mPGES-1 and COX after local GC treatment [3], resulting in a diminished PGE₂ generation. Thus, the attenuated 15-PGDH expression observed here may reflect simply a negative feedback induced by low PGE₂ availability. Also, although PGE₂ has a pivotal role in bone remodeling and degradation [28], complete removal of PGE₂ may not be beneficial as there is evidence for a protective role for basal PGE₂ in the resolution phase of inflammation [29-31] as well as for suppression of B-cell proliferation by PGE₂ [32]. Furthermore, it is important to keep in mind that 15-PGDH, though the key enzyme for

catabolism of prostaglandins, is also involved in degradation of lipoxins [33], with essentially opposed activity in the inflammatory milieu. As such, the lack of effect or trend toward decreased 15-PGDH reported here by GC may, in fact, contribute to preserving anti-inflammatory lipid mediators.

Given the limitation of the analytical system used in our study, we cannot rule out that the change in positive staining may be the result of a decrease in the number of inflammatory cells expressing the enzymes rather than an actual reduction in cellular expression. Data from a previous study demonstrated that intra-articular corticosteroid therapy reduced the number of synovial T lymphocytes but that the number of macrophages remained unchanged [34]. Since mPGES-1, 15-PGDH, and the COX enzymes are detected mainly in the macrophage and fibroblast populations but are essentially lacking in synovial lymphocytes, it is reasonable to assume that the changes we detect may be due to both reduced cellular enzyme formation and reduced inflammatory cell infiltration.

Despite being the first line of therapy for RA [35] and highly efficient in many patients, oral methotrexate showed no significant influence on the enzymes coordinating PGE₂ metabolism. Image analysis of mPGES-1 expression, though not detecting any statistically significant change, showed that only four out of 13 patients displayed an increased mPGES-1 staining but that in all others methotrexate decreased the positive stained area. Thus, we cannot exclude an actual effect of the given therapy toward decreased mPGES-1, had we had a larger study cohort. On the other hand, the lack of effect on the 15-PGDH levels seen in our group of newly diagnosed subjects suggests local persistence of PGE₂ in these patients. In fact, PGE₂ availability despite methotrexate therapy could explain the progression in joint erosion seen in some of the responder patients. It is well known that methotrexate, through folate-dependent biosynthetic blockade, causes upstream accumulation of adenosine that turns on anti-inflammatory pathways by acting predominantly on A2A and A3 receptors [36]. In fact, experimental and clinical data suggest that the adenosine-mediated anti-inflammatory effect is the most prominent mechanism for low-dose methotrexate efficiency in RA. In this sense, inhibition of TNF [37] and IL-1β [38] actions and enhanced IL-10 [39] production were reported as indirect effects through adenosine release. Several reports suggest that methotrexate, administered either *in vivo* in animal models of arthritis [40] or added *in vitro* in different cell systems such as rat peritoneal macrophages [41] and human rheumatoid synoviocytes [20], may have inhibitory effects on PGE₂ production. There is, however, evidence that methotrexate may fail to elicit a change in PGE₂ in human fibroblasts [22,42]. Although study conditions and

systems differ in the aforementioned studies, a clear and definite effect of methotrexate on the prostaglandin pathway in synovium-derived cells is not apparent. Our *in vitro* results demonstrated that, in RA FLSs, methotrexate had no influence on the PGE₂ pathway or on any of the COX-derived lipid mediators. The increase in 15-PGDH expression following IL-1 β treatment of synovial fibroblasts may be secondary to the high PGE₂ amount formed under these circumstances, as PGE₂ itself may induce 15-PGDH mRNA expression [43].

An earlier study evaluating synovial biopsies after 4 months of methotrexate treatment indicated that the macrophages and lymphocyte populations are reduced in the RA synovium [44]. Recent data from the same cohort of patients as the one used in our study demonstrated that 8 weeks of oral methotrexate therapy reduced the number of synovial CD3-positive lymphocytes and, to a lesser extent, the CD68-positive macrophages (Shankar Revu, submitted manuscript). Although lining and sublining macrophages highly express the enzymes involved in PGE₂ formation, we found no significant influence exerted by methotrexate in our study. However, our study was designed to detect early changes in the synovium after the start of therapy and thus additional effects may become evident later on.

Conclusions

15-PGDH is present in synovial tissue in conditions associated with inflammatory responses, such as OA, PsA, and RA, in a manner similar to that of the PGE₂-synthesizing enzymes. Local GC treatment seems to reduce its expression, whereas oral methotrexate therapy exerts little influence in synovial tissue or in FLSs *in vitro*. Together, these results suggest that the inflammation-induced PGE₂ pathway may not be properly targeted by anti-rheumatic treatment but instead persists and contributes to perpetuating inflammatory circuits in the rheumatoid synovium. As such, therapeutical attempts aiming at blocking the excessive production of PGE₂ may be justified in order to offer additional benefit in reducing synovial inflammation and damage.

Abbreviations

15-PGDH: 15-prostaglandin dehydrogenase; COX: cyclooxygenase; DAS28: Disease Activity Score in 28 joints; FLS: fibroblast-like synoviocyte; GC: glucocorticoid; IL: interleukin; LC-MS-MS: liquid chromatography tandem mass spectrometry; mPGES-1: microsomal prostaglandin E₂ synthase 1; NSAID: non-steroidal anti-inflammatory drug; OA: osteoarthritis; PBS: phosphate-buffered saline; PG: prostaglandin; PsA: psoriatic arthritis; RA: rheumatoid arthritis; TNF: tumor necrosis factor; TTBS: Tris-Tween-buffered saline; Tx: tromboxane.

Acknowledgements

This study was supported by grants from the Swedish Research Council, the Swedish Rheumatism Association, King Gustaf V 80 years Foundation, the Swedish Society of Medicine, the Karolinska Institutet Foundation, and VINNOVA.

Author details

¹Department of Medicine, Rheumatology Unit, Karolinska Institute/Karolinska University Hospital Solna, Stockholm, 171 76 Sweden. ²Institute for Clinical Pharmacology, Johann Wolfgang Goethe-University Frankfurt, Theodor Stern Kai 7, 60590 Frankfurt/Main, Germany. ³Actar AB, Nobels väg 3, Solna, 171 65 Sweden.

Authors' contributions

KRG participated in the study design, carried out the immunohistochemistry staining and analysis, performed statistical data analysis, and drafted the manuscript. SS carried out the Western blot analysis. IW performed the initial immunohistochemistry studies. PL participated in Western blot data collection and interpretation. HI carried out the mass spectrometry studies. AIC contributed to study design and collection of patient data and samples. MK conceived the study, participated in its design and coordination, and contributed to manuscript drafting and revision. P-JJ contributed to study design, data interpretation, and manuscript revision. All authors read and approved the final manuscript.

Competing interests

MK is employed part-time by Actar AB. The other authors declare that they have no competing interests.

Received: 13 January 2012 Revised: 20 April 2012

Accepted: 22 May 2012 Published: 22 May 2012

References

- Westman M, Korotkova M, af Klint E, Stark A, Audoly LP, Klareskog L, Ulfgren AK, Jakobsson PJ: **Expression of microsomal prostaglandin synthase 1 in rheumatoid arthritis synovium.** *Arthritis Rheum* 2004, **50**:1774-1780.
- Fitzpatrick FA: **Cyclooxygenase enzymes: regulation and function.** *Curr Pharm Des* 2004, **10**:577-588.
- Korotkova M, Westman M, Gheorghe KR, af Klint E, Trollmo C, Ulfgren AK, Klareskog L, Jakobsson PJ: **Effects of antirheumatic treatments on the prostaglandin E2 biosynthetic pathway.** *Arthritis Rheum* 2005, **52**:3439-3447.
- Chizzolini C, Chicheportiche R, Alvarez M, de Rham C, Roux-Lombard P, Ferrari-Lacraz S, Dayer JM: **Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion.** *Blood* 2008, **112**:3696-3703.
- Thoren S, Jakobsson PJ: **Coordinate up- and down-regulation of glutathione-dependent prostaglandin synthase and cyclooxygenase-2 in A549 cells. Inhibition by NS-398 and leukotriene C4.** *Eur J Biochem* 2000, **267**:6428-6434.
- Tai HH, Ensor CM, Tong M, Zhou H, Yan F: **Prostaglandin catabolizing enzymes.** *Prostaglandins Other Lipid Mediat* 2002, **68-69**:483-493.
- Tong M, Tai HH: **Synergistic induction of the nicotinamide adenine dinucleotide-linked 15-hydroxyprostaglandin dehydrogenase by an androgen and interleukin-6 or forskolin in human prostate cancer cells.** *Endocrinology* 2004, **145**:2141-2147.
- Otani T, Iwasaki M, Inoue M, Sasazuki S, Tsugane S: **Bowel movement, state of stool, and subsequent risk for colorectal cancer: the Japan public health center-based prospective study.** *Ann Epidemiol* 2006, **16**:888-894.
- Tong M, Ding Y, Tai HH: **Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells.** *Carcinogenesis* 2006, **27**:2170-2179.
- Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, Milne GL, Katkuri S, DuBois RN: **15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer.** *J Biol Chem* 2005, **280**:3217-3223.
- Tai HH, Tong M, Ding Y: **15-Hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer.** *Prostaglandins Other Lipid Mediat* 2007, **83**:203-208.
- Quidville V, Segond N, Lausson S, Frenkian M, Cohen R, Jullienne A: **15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line.** *Prostaglandins Other Lipid Mediat* 2006, **81**:14-30.
- Ivanov AI, Romanovsky AA: **Prostaglandin E2 as a mediator of fever: synthesis and catabolism.** *Front Biosci* 2004, **9**:1977-1993.
- Gosset M, Berenbaum F, Salvat C, Sautet A, Pigenet A, Tahir K, Jacques C: **Crucial role of visfatin/pre-B cell colony-enhancing factor in matrix**

- degradation and prostaglandin E2 synthesis in chondrocytes: possible influence on osteoarthritis. *Arthritis Rheum* 2008, **58**:1399-1409.
15. Gosset M, Berenbaum F, Levy A, Pigenet A, Thirion S, Cavadas S, Jacques C: Mechanical stress and prostaglandin E2 synthesis in cartilage. *Biorheology* 2008, **45**:301-320.
 16. Tong M, Tai HH: 15-Hydroxyprostaglandin dehydrogenase can be induced by dexamethasone and other glucocorticoids at the therapeutic level in A549 human lung adenocarcinoma cells. *Arch Biochem Biophys* 2005, **435**:50-55.
 17. Tong M, Tai HH: Dexamethasone inhibits the induction of NAD (+)-dependent 15-hydroxyprostaglandin dehydrogenase by phorbol ester in human promonocytic U937 cells. *Biochim Biophys Acta* 2000, **1497**:61-68.
 18. Visser K, Verpoort KN, van Dongen H, van der Kooij SM, Allaart CF, Toes RE, Huizinga TW, van der Helm-van Mil AH: Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis. *Ann Rheum Dis* 2008, **67**:1194-1195.
 19. Mello SB, Barros DM, Silva AS, Laurindo IM, Novaes GS: Methotrexate as a preferential cyclooxygenase 2 inhibitor in whole blood of patients with rheumatoid arthritis. *Rheumatology (Oxford)* 2000, **39**:533-536.
 20. Vergne P, Liagre B, Bertin P, Cook-Moreau J, Treves R, Beneytout JL, Rigaud M: Methotrexate and cyclooxygenase metabolism in cultured human rheumatoid synoviocytes. *J Rheumatol* 1998, **25**:433-440.
 21. Seitz M, Loetscher P, Dewald B, Towbin H, Baggiolini M: In vitro modulation of cytokine, cytokine inhibitor, and prostaglandin E release from blood mononuclear cells and synovial fibroblasts by antirheumatic drugs. *J Rheumatol* 1997, **24**:1471-1476.
 22. Meyer FA, Yaron I, Mashiah V, Yaron M: Methotrexate inhibits proliferation but not interleukin 1 stimulated secretory activities of cultured human synovial fibroblasts. *J Rheumatol* 1993, **20**:238-242.
 23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TM Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988, **31**:315-324.
 24. Gheorghe KR, Korotkova M, Catrina AI, Backman L, af Klint E, Claesson HE, Radmark O, Jakobsson PJ: Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids. *Arthritis Res Ther* 2009, **11**:R83.
 25. Ulfgren AK, Lindblad S, Klareskog L, Andersson J, Andersson U: Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. *Ann Rheum Dis* 1995, **54**:654-661.
 26. Schneider A, Zhang Y, Zhang M, Lu WJ, Rao R, Fan X, Redha R, Davis L, Breyer RM, Harris R, Guan Y, Breyer MD: Membrane-associated PGE synthase-1 (mPGES-1) is coexpressed with both COX-1 and COX-2 in the kidney. *Kidney Int* 2004, **65**:1205-1213.
 27. Korotkova M, Helmers SB, Loell I, Alexanderson H, Grundtman C, Dorph C, Lundberg IE, Jakobsson PJ: Effects of immunosuppressive treatment on microsomal prostaglandin E synthase 1 and cyclooxygenases expression in muscle tissue of patients with polymyositis or dermatomyositis. *Ann Rheum Dis* 2008, **67**:1596-1602.
 28. Blackwell KA, Raisz LG, Pillbeam CC: Prostaglandins in bone: bad cop, good cop? *Trends Endocrinol Metab* 2010, **21**:294-301.
 29. Chan MM, Moore AR: Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production. *J Immunol* 2008, **184**:6418-6426.
 30. Su WH, Cheng MH, Lee WL, Tsou TS, Chang WH, Chen CS, Wang PH: Nonsteroidal anti-inflammatory drugs for wounds: pain relief or excessive scar formation? *Mediators Inflamm* 2010, **2010**:413238.
 31. Degousee N, Fazel S, Angoulvant D, Stefanski E, Pawelzik SC, Korotkova M, Arab S, Liu P, Lindsay TF, Zhuo S, Butany J, Li RK, Audoly L, Schmidt R, Angioni C, Geisslinger G, Jakobsson PJ, Rubin BB: Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. *Circulation* 2008, **117**:1701-1710.
 32. Murn J, Alibert O, Wu N, Tendil S, Gidrol X: Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Ptger4. *J Exp Med* 2008, **205**:3091-3103.
 33. Clish CB, Levy BD, Chiang N, Tai HH, Serhan CN: Oxidoreductases in lipoxin A4 metabolic inactivation: a novel role for 15-onoprostaglandin 13-reductase/leukotriene B4 12-hydroxydehydrogenase in inflammation. *J Biol Chem* 2000, **275**:25372-25380.
 34. af Klint E, Grundtman C, Engstrom M, Catrina AI, Makrygiannakis D, Klareskog L, Andersson U, Ulfgren AK: Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels. *Arthritis Rheum* 2005, **52**:3880-3889.
 35. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, Bombardier C, Carmona L, van der Heijde D, Bijlsma JW, Boumpas DT, Canhao H, Edwards CJ, Hamuryudan V, Kvien TK, Leeb BF, Martin-Mola EM, Mielants H, Müller-Ladner U, Murphy G, Østergaard M, Pereira IA, Ramos-Remus C, Valentini G, Zochling J, Dougados M: Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. *Ann Rheum Dis* 2009, **68**:1086-1093.
 36. Tian H, Cronstein BN: Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. *Bull NYU Hosp Jt Dis* 2007, **65**:168-173.
 37. Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS: Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. *J Immunol* 1996, **156**:3435-3442.
 38. Seitz M, Loetscher P, Dewald B, Towbin H, Rordorf C, Gallati H, Baggiolini M, Gerber NJ: Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. *Br J Rheumatol* 1995, **34**:602-609.
 39. Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES: Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. *J Immunol* 1996, **157**:4634-4640.
 40. Novaes GS, Mello SB, Laurindo IM, Cossermelli W: Low dose methotrexate decreases intraarticular prostaglandin and interleukin 1 levels in antigen induced arthritis in rabbits. *J Rheumatol* 1996, **23**:2092-2097.
 41. Williams A, Goodfellow R, Topley N, Amos N, Williams B: The suppression of rat collagen-induced arthritis and inhibition of macrophage derived mediator release by liposomal methotrexate formulations. *Inflamm Res* 2000, **49**:155-161.
 42. Inoue H, Takamori M, Nagata N, Nishikawa T, Oda H, Yamamoto S, Koshihara Y: An investigation of cell proliferation and soluble mediators induced by interleukin 1beta in human synovial fibroblasts: comparative response in osteoarthritis and rheumatoid arthritis. *Inflamm Res* 2001, **50**:65-72.
 43. Frenkian M, Pidoux E, Baudoin C, Segond N, Jullienne A: Indomethacin increases 15-PGDH mRNA expression in HL60 cells differentiated by PMA. *Prostaglandins Leukot Essent Fatty Acids* 2001, **64**:87-93.
 44. Dolhain RJ, Tak PP, Dijkmans BA, De Kuiper P, Breedveld FC, Miltenburg AM: Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. *Br J Rheumatol* 1998, **37**:502-508.

doi:10.1186/ar3851

Cite this article as: Gheorghe et al.: Limited effect of anti-rheumatic treatment on 15-prostaglandin dehydrogenase in rheumatoid arthritis synovial tissue. *Arthritis Research & Therapy* 2012 **14**:R121.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit